Literature DB >> 17970823

Acute bacterial conjunctivitis.

Gunnar Høvding1.   

Abstract

Acute bacterial conjunctivitis is the eye disease most commonly seen by general practitioners, and is estimated to represent approximately 1% of all consultations in primary care. This article gives a review of the epidemiology, aetiology, clinical picture, complications, differential diagnoses, in vitro examinations and therapy of acute bacterial conjunctivitis. Until now, topical antibacterial therapy has generally been preferred by both physicians and patients because this will usually shorten the course of the disease slightly and allow the early readmittance of children to their kindergarten or school. Recently, several reports from primary care have confirmed the well-known clinical experience that the disorder has an excellent prognosis with a high frequency of spontaneous remission. In accordance, an expectant attitude or delayed prescription policy are now frequently strongly recommended. However, these reports also emphasize the difficulty in making a correct clinical distinction between bacterial and viral conjunctivitis. The effect of a general non-prescription attitude on transmission rates of pathogens also remains to be clarified. This must be born in mind when deciding how these patients should be handled. The socioeconomic and medical pros and cons of different treatment policies are discussed, and a highly personal view on the optimal handling strategy for these patients is also presented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970823     DOI: 10.1111/j.1600-0420.2007.01006.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  44 in total

1.  Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary.

Authors:  Adebukola Adebayo; Jignesh G Parikh; Steven A McCormick; Mahendra K Shah; Remedios S Huerto; Guopei Yu; Tatyana Milman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-08       Impact factor: 3.117

2.  Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells.

Authors:  Megha Barot; Mitan R Gokulgandhi; Megan Haghnegahdar; Pranjali Dalvi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2011-08-10       Impact factor: 2.671

Review 3.  Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

4.  [Rational antibiotic therapy in ophthalmology].

Authors:  W Behrens-Baumann; U Frank; T Ness
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

5.  Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.

Authors:  Jesse DeLeon; Bruce E Silverstein; Catherine Allaire; Lynne S Gearinger; Kirk M Bateman; Timothy W Morris; Timothy L Comstock
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

6.  Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.

Authors:  Timothy L Comstock; Michael R Paterno; Heleen H Decory; Dale W Usner
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  Mucosal erosions as the presenting symptom in erythema multiforme: a case report.

Authors:  Stephen Spencer; Thajunnisha Buhary; Ian Coulson; Sedki Gayed
Journal:  Br J Gen Pract       Date:  2016-03       Impact factor: 5.386

8.  Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.

Authors:  Timothy L Comstock; Michael R Paterno; Dale W Usner; Michael E Pichichero
Journal:  Paediatr Drugs       Date:  2010-04-01       Impact factor: 3.022

9.  Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration.

Authors:  Gail Torkildsen; Joel W Proksch; Aron Shapiro; Stephanie K Lynch; Timothy L Comstock
Journal:  Clin Ophthalmol       Date:  2010-04-26

10.  Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Authors:  Joseph S Bertino
Journal:  Clin Ophthalmol       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.